On Thursday, Microsoft Corporation (NASDAQ:MSFT)’s shares declined -1.47% to $55.48. Microsoft Corporation (NASDAQ:MSFT) is now worth about $449.80 billion. The share price has made a 2.49% gain in the past 5 days and has gained 15.87% since 2015 kicked off. Analysts are forecasting EPS growth of 1.49% for next fiscal year and 9.13% growth in the next 5 years. The stock trades with a beta of 0.98. The stock price is above by 18.25% as contrast to the average price over the last 200 days. The company has 13.50% gross margins.
Microsoft (MSFT) shares are presently priced at 20.56x this year’s forecasted earnings, which makes them relatively expensive contrast to the industry’s 12.56x earnings multiple for the same period. The company pays shareholders $1.44 per share in dividend income per year, for a current yield of 2.55%.
According to a consensus of 27 analysts, the earnings estimate of $0.71 per share would be $0.00 worse than the year-ago quarter and a $0.01 sequential decrease. The full-year EPS estimate is $2.75 which would be a $0.29 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $25.23 Billion. If stated, that would be a 4.68% decrease over the year-ago quarter.
Microsoft Corporation is engaged in developing, licensing and supporting a range of software products and services. The Company also designs and sells hardware, and delivers online advertising to the customers. The Company operates in five segments: Devices and Consumer (D&C) Licensing, D&C Hardware, D&C Other, Commercial Licensing, and Commercial Other.
Bank of America Corp (NYSE:BAC)’s shares dropped -1.26% to $16.83. With its recent share price change, BAC market value has reached roughly $177.53 billion. The company has a Profit Margin (ttm) of positive 30.40%. The operating profit margin is 74.10%. The stock’s performance in 1 month is -5.24% and its volatility for the same period is 1.22%.
Bank of America recently declared the redemption of $2.0 billion of trust preferred securities. Starting in January of 2016, these securities, unlike the corporation’s other outstanding series of trust preferred securities, will completely phase out from regulatory capital.
As a result of the Bank of America Merrill Lynch merger in 2009, the company recorded a discount to par value as purchase accounting adjustments associated with these securities. Bank of America will record a non-cash reduction to net interest income and to pretax income of about $600 million in the fourth quarter of 2015 for the remaining discount to par value. The company anticipates realizing cash savings from lower funding costs as a result of the redemption.
The redemption affects all of the trust preferred securities of each trust listed in the table below. The redemption date for all such trust preferred securities is January 29, 2016, and the redemption price is 100 percent of the liquidation amount per trust preferred security, plus accumulated and unpaid distributions on the trust preferred securities through the redemption date.
Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers, small- and middle-market businesses, institutional investors, corporations and Governments with a range of banking, investing, asset management and other financial and risk management products and services.
Chimerix Inc (NASDAQ:CMRX)‘s shares surged 7.19% to $8.95. The last trading range of Chimerix Inc (NASDAQ:CMRX) ranges between $8.71 and $9.75. The EPS of the company stands at $-2.34. The 52-week range shows that the stock reached higher at $58.04 while its lower range is $6.43 in the last 52-weeks. The average volume of the company is at 2.17 million with the Outstanding Shares of 46.15 million. The market capitalization of the company is $385.32 million. The RSI (Relative Strength Index) of 14.60.
Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
